Diagnostics group: Qiagen appoints Jonathan Pratt as new Group CEO
Pratt will replace Thierry Bernard, whose departure was confirmed at the end of last year. The outgoing CEO is supposed to accompany the transition until the end of the year.
Frankfurt - Diagnostikkonzern Qiagen has appointed industry veteran Jonathan Pratt as its new chief executive officer, effective from September 1st. The company announced this on Monday, stating that Pratt will be replacing Thierry Bernard, whose departure has been expected since the end of last year. Pratt possesses over 25 years of experience in the field and recently led the Filtration Group until its sale to Parker-Hannifin in August.
Prior to that, he held senior positions at companies like Waters Corporation and Danaher's Beckman Coulter. Despite this leadership change, Qiagen remains committed to its targets for the current quarter and for the fiscal year 2026. The strategic review of the business will continue, with the board of directors, assisted by consultants, exploring ways to increase the company's value for shareholders.
Thierry Bernard, who has been at the helm since March 2020, is expected to oversee the transition until the end of the year. Qiagen looks optimistic about 2026 with an anticipated increase in margins.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
